Physician profile
Dana E Greer
NPI 1992210991
$1,927.17
in general payments reported to CMS, 2019-2025
21 companies · $868 in 2025
The $868 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.93 · 2023: $119 · 2024: $902 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $610.27 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Viiv Healthcare Company | $255.09 | 2024-2025 | Apretude |
| Lilly USA, LLC | $187.17 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $164.84 | 2023-2025 | Wegovy, Ozempic |
| Exact Sciences Corporation | $94.65 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $78.06 | 2023-2024 | |
| Dexcom, INC. | $76.13 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $65.25 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $62.94 | 2024-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.50 | 2024-2025 | Xifaxan, Trulance |
| Azurity Pharmaceuticals, INC. | $41.90 | 2025 | Azmiro |
| Gilead Sciences, INC. | $38.85 | 2025 | |
| Xeris Pharmaceuticals, INC. | $37.93 | 2022 | |
| Esperion Therapeutics, INC. | $29.86 | 2024-2025 | Nexletol |
| Inspire Medical Systems, INC. | $26.77 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.16 | 2024 | Rexulti |
| Radius Health, INC. | $20.67 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.45 | 2025 | Jardiance |
| Abbvie INC. | $18.49 | 2024 | |
| Tolmar, INC. | $15.58 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $14.61 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.